Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 8/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | P4HB | P07237 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | ADH5 | P11766 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3308020 | 0.89 | KDM4E (0.41) | SRD5A2HPGDNPSR1HTR3AHRH4 | |
| Hydrochloric Acid SCHEMBL3562874 | 0.88 | HRH4 (0.37) | SRD5A2HPGDNPSR1HTR3AHRH4 | |
| SCHEMBL16334973 | 0.86 | EGFR (0.44) | SRD5A2HPGDNPSR1TTRMEN1 | |
| SCHEMBL3561016 | 0.83 | ALDH1A1 (0.43) | SRD5A2HPGDSMN1; SMN2 | |
| SCHEMBL274525 | 0.79 | NR1H2 (0.50) | HPGDMEN1KMT2ASMN1; SMN2HTR3A | |
| SCHEMBL16380723 | 0.76 | EGFR (0.42) | SRD5A2HPGDNPSR1KMT2A | |
| SCHEMBL3533360 | 0.73 | TTR (0.59) | TTR | |
| SCHEMBL23149200 | 0.73 | CES2 (0.44) | SRD5A2HPGDMEN1KMT2AHRH4 | |
| SCHEMBL988152 | 0.73 | SMN1; SMN2 (0.46) | SRD5A2TTRSMN1; SMN2P4HBTDP1 | |
| SCHEMBL1742861 | 0.72 | HPGD (0.45) | SRD5A2HPGDNPSR1TTRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3299358-A1 | AMIDE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2018-03-28 | — | — | EP | disclosed |
| EP-1702917-B1 | AMIDE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 2017-08-02 | — | — | EP | disclosed |
| US-7728131-B2 | 3-difluoromethyl-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide, having excellent tyrosine kinase inhibitory activity, used as therapeutic agent for leukemia | NIPPON SHINYAKU CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080293940-A1 | Amide Derivative and Medicine | NIPPON SHINYAKU CO., LTD. (JP) | 2008-11-27 | — | — | US | disclosed |
| EP-1702917-A1 | AMIDE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293940-A1 | Amide Derivative and Medicine | ABL2, ABL1, BCR | SRD5A2 2573/4885HPGD 994/4885NPSR1 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.